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Microglial inflammatory activity is thought to be a major contributor to the pathology of neurodegenerative conditions such as
Alzheimer’s disease (AD), and strategies to restrain their behaviour are under active investigation. Classically, anti-inflammatory
approaches are aimed at suppressing proinflammatory mediator production, but exploitation of inflammatory resolution, the
endogenous process whereby an inflammatory reaction is terminated, has not been fully investigated as a therapeutic approach
in AD. In this study, we sought to provide proof-of-principle that the major proresolving actor, formyl peptide receptor 2, Fpr2,
could be targeted to reverse microglial activation induced by the AD-associated proinflammatory stimulus, oligomeric β-
amyloid (oAβ). The immortalised murine microglial cell line BV2 was employed as a model system to investigate the
proresolving effects of the Fpr2 ligand QC1 upon oAβ-induced inflammatory, oxidative, and metabolic behaviour. Cytotoxic
behaviour of BV2 cells was assessed through the use of cocultures with retinoic acid-differentiated human SH-SY5Y cells.
Stimulation of BV2 cells with oAβ at 100 nM did not induce classical inflammatory marker production but did stimulate
production of reactive oxygen species (ROS), an effect that could be reversed by subsequent treatment with the Fpr2 ligand
QC1. Further investigation revealed that oAβ-induced ROS production was associated with NADPH oxidase activation and a
shift in BV2 cell metabolic phenotype, activating the pentose phosphate pathway and NADPH production, changes that were
again reversed by QC1 treatment. Microglial oAβ-stimulated ROS production was sufficient to induce apoptosis of bystander
SH-SY5Y cells, an effect that could be prevented by QC1 treatment. In this study, we provide proof-of-concept data that
indicate exploitation of the proresolving receptor Fpr2 can reverse damaging oAβ-induced microglial activation. Future
strategies that are aimed at restraining neuroinflammation in conditions such as AD should examine proresolving actors as a
mechanism to harness the brain’s endogenous healing pathways and limit neuroinflammatory damage.
1. Background
AD is the single greatest cause of dementia, affecting approx-
imately 4% of individuals aged over 65 years and with a
global disease burden of around 37 million individuals [1].
This figure is set to increase as the population ages and is
expected to reach around 78 million people by 2050 [2].
There are currently no effective treatments for the condition.
Whilst the two core pathological lesions of AD, extracel-
lular β-amyloid (Aβ) plaques and intraneuronal tau tangles,
have long been studied, the contribution to pathology pro-
vided by neuroinflammation, and the role of the microglia
in AD pathogenesis, has only recently been appreciated [3,
4]. Several lines of evidence indicate a pathological role for
microglial activity: studies of genetic risk factors for idio-
pathic AD have identified numerous immune-related risk
loci, clinical imaging studies have indicated a positive corre-
lation between microglial activity and both Aβ load and
neurodegeneration [5], and chronic neuroinflammation is
considered a feature of multiple independent animal models
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of the disease [6]. More directly, Aβ can act as a damage-
associated molecular pattern [7], stimulating microglial acti-
vation through a range of different receptors, including the
receptor for advanced glycation end products, toll-like recep-
tors, and CD36 [8].
Under normal conditions, inflammation is self-resolving,
with numerous factors acting to “switch off” inflammatory
processes [9]. A central actor in this process is the G
protein-coupled receptor formyl peptide receptor 2 (FPR2)
or its murine functional homologues Fpr2/3 [10]. Strong evi-
dence exists for the proresolving potential of this receptor in
peripheral inflammation, where it promotes neutrophil apo-
ptosis [11] and regulates monocyte/macrophage recruitment
[12, 13], phenotype [14], and behaviour [15]. Importantly,
protective effects have been identified for this receptor in
diverse inflammatory settings, including sepsis [16], heart
failure [17], and atherosclerosis [18].
Expression of FPR2 within the brain has been reported in
the endothelium and in selected hippocampal and cerebellar
neurons [19], but it is also expressed by microglia [20] and is
rapidly upregulated following inflammatory insult [21]. Sig-
nificantly, FPR2 expression has been reported in inflamma-
tory cells infiltrating Aβ plaques in AD [22], is involved in
chemotaxis to high concentrations of Aβ [23], and has been
indirectly implicated in microglial Aβ phagocytosis [24].
Given the importance of this receptor in the resolution of
peripheral inflammation, we hypothesised that FPR2 ago-
nists would be able to reverse the proinflammatory effects
of Aβ upon microglia, restoring normal homeostasis.
2. Methods
2.1. Drugs and Reagents. The FPR2 agonist Quin-C1 (QC1;
4-butoxy-N-[1,4-dihydro-2-(4-methoxyphenyl)-4-oxo-3(2H)-
quinazolinyl]benzamide) and antagonist WRW4 (Trp-Arg-
Trp-Trp-Trp-Trp-NH2) were purchased from Tocris Ltd.,
UK. Isolated and purified lipopolysaccharides developed in
Escherichia coli, serotype O111:B4, were purchased from
Merck Millipore, Ltd., UK. HFIP-treated human Aβ1-42 pep-
tide was purchased from JPT Peptide Technologies, Berlin,
Germany.
2.2. Aβ Oligomerisation. HFIP-treated Aβ1-42 stored at -80
°C
in DMSO was oligomerised by dilution and vortexing in PBS
followed by incubation overnight at 4°C [25]. Oligomer for-
mation was confirmed by native tricine-SDS-polyacrylamide
gel electrophoresis. Briefly, 2μg oligomeric Aβ (oAβ) was
resuspended in nondenaturing sample buffer (62.5mM
Tris-base, 25% glycerol, and 1% (w/v) Coomassie Blue R-
250) and loaded onto a 10% acrylamide : bis-acrylamide gel
and separated by electrophoresis alongside molecular weight
markers. Gels were incubated with Coomassie stain (60mg/l
Coomassie Blue R-250 and 10% v/v acetic acid, both from
Sigma-Aldrich, UK). Following 24 h destaining in 10% v/v
acetic acid and 50% v/v methanol (Sigma-Aldrich, UK), gels
were imaged using a ChemiDoc MP Imaging System (Bio-
Rad Ltd., UK). Oligomeric Aβ migrated at approximately
35 kDa, indicating the presence of hexamers/heptamers
(Supplementary Figure 1).
2.3. Cell Culture. The murine microglial line BV2 was a gen-
erous gift from Prof. E. Blasi (Università degli Studi di
Modena e Reggio Emilia, Italy); the human neuroblastoma
SH-SY5Y line was purchased from the European Collection
of Authenticated Cell Cultures (ECACC, Salisbury, UK).
Both lines were cultured in DMEM medium supplemented
with 5% fetal calf serum and 100μM nonessential amino
acids, 2mM L-alanyl-L-glutamine, and 50mg/ml penicillin-
streptomycin (all from Thermo Fisher Scientific, UK) at
37°C in a 5% CO2 atmosphere. SH-SY5Y cells were differen-
tiated to a neuron-like phenotype prior to experimentation
by incubation with 10μM trans-retinoic acid (Sigma-
Aldrich, UK) for 5 days [26].
Primary murine microglia were prepared from C57Bl/6
male mice aged 8 weeks according to our previously pub-
lished protocols [27]. Cells were cultured in DMEMmedium
supplemented with 20% fetal calf serum and 100μM non-
essential amino acids, 2mM L-alanyl-L-glutamine, and
50mg/ml penicillin-streptomycin (all Thermo Fisher Sci-
entific, UK) at 37°C in a 5% CO2 atmosphere.
2.4. Reactive Oxygen Species (ROS) Assays. Total intracellular
ROS production was quantified using 6-chloromethyl-2′,7′-
dichlorodihydrofluorescein diacetate, acetyl ester (CM-
H2DCFDA; Thermo Fisher Scientific, UK) according to the
manufacturer’s recommendations. Briefly, cells were plated
at 200,000 cells/cm2 in phenol red-free DMEM, serum
starved overnight, and preloaded with 5μM CM-H2DCFDA
for 20 minutes at 37°C. Following removal of unbound dye,
fresh phenol red-free DMEM was added and experimental
treatments were begun. Following administration of treat-
ments, cellular fluorescence was determined every 5 minutes
for 1 hr at 37°C using a CLARIOstar fluorescence microplate
reader (BMG Labtech, Germany) with excitation and emis-
sion filters set at 492 nm and 517nm, respectively. Primary
microglia were treated in the same way, except that due
to lower numbers of cells, fluorescence was analysed at
the end of 1-hour incubation periods by flow cytometry
using a FACSCanto II flow cytometer (BD Biosciences, UK)
equipped with a 488nm laser and FlowJo 8.8.1 software
(TreeStar Inc., FL, USA). A total of 10,000 singlet events
per sample were quantified.
Mitochondrial superoxide production was quantified
using the tracer MitoSOX Red (Thermo Fisher Scientific,
UK) according to the manufacturer’s recommendations
and a loading concentration of 2.5μM. Following adminis-
tration of treatments, cellular fluorescence was determined
every 5 minutes for 1 hr at 37°C using a CLARIOstar fluo-
rescence microplate reader (BMG Labtech, Germany) with
excitation and emission filters set at 510nm and 580 nm,
respectively.
Hydrogen peroxide production was quantified using the
ROS-Glo H2O2 Assay (Promega, Southampton, UK) accord-
ing to the manufacturer’s recommendations. Following
experimental treatment, luminescence of cell lysates at 37°C
was determined using a CLARIOstar luminescence micro-
plate reader (BMG Labtech, Germany), in comparison to a
H2O2 standard curve (0.013μM-10mM).
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2.5. GSH :GSSG Ratio Analysis. The ratio of reduced (GSH)
to oxidised (GSSG) glutathione was determined using a com-
mercial assay (GSH :GSSG-Glo assay, Promega, Southamp-
ton, UK) according to the manufacturer’s instructions, with
cells plated at 200,000 cells/cm2 on black-walled 96-well
plates. A CLARIOstar spectrophotometer (BMG Labtech,
Germany) was used to measure relative luminescence with
comparison to a total glutathione standard curve (0.25μM-
16μM).
2.6. Cytokine ELISA. Tumour necrosis factor alpha (TNFα)
was assayed by murine-specific sandwich ELISA using com-
mercially available kits, according to the manufacturer’s
protocols (Thermo Fisher Scientific, UK). A CLARIOstar
spectrophotometer (BMG Labtech, Germany) was used to
measure absorbance at 450nm.
2.7. E. coli Bioparticle Phagocytosis. Microglial phagocytic
capacity was determined using BODIPY FL-conjugated
Escherichia coli (K-12 strain) bioparticles (Thermo Fisher
Scientific, UK). Following experimental treatments, cells
were incubated with bioparticle conjugates at a ratio of 50
particles per cell in PBS for 30 minutes at 37°C in the dark.
Cells were washed, fluorescence of nonengulfed particles
was quenched by the addition of 0.2% Trypan blue (Thermo
Fisher Scientific, UK) for 1min, and cellular fluorescence was
determined using a FACSCanto II flow cytometer (BD Bio-
sciences, UK) equipped with a 488 nm laser and FlowJo
8.8.1 software (TreeStar Inc., FL, USA). A total of 10,000 sin-
glet events per sample were quantified.
2.8. Flow Cytometry. BV2 or SH-SY5Y cells alone or in
coculture were labelled with APC-conjugated rat monoclo-
nal anti-mouse CD11b, PE-Cy7-conjugated rat monoclonal
anti-mouse CD40, or PerCP-Cy5.5-conjugated mouse mono-
clonal anti-human CD200 (all from BioLegend, UK) for anal-
ysis by flow cytometry. Immunofluorescence was analysed for
10,000 singlet events per sample using a FACSCanto II flow
cytometer (BD Biosciences, UK); data were analysed using
FlowJo 8.8.1 software (TreeStar Inc., FL, USA).
2.9. Annexin A5 Apoptosis Assay. SH-SY5Y cells were differ-
entiated as described above and treated according to experi-
mental design, either alone or in coculture with BV2 cells.
Cultures were incubated in PBS, detached using a cell
scraper, and incubated with FITC-conjugated Annexin A5
(0.45μg/ml in 0.01M PBS, 0.1% bovine serum albumin,
and 1mM CaCl2), and in the case of cocultures, incubated
with APC-conjugated rat monoclonal anti-mouse CD11b
and PerCP-Cy5.5-conjugated mouse monoclonal anti-human
CD200 (all BioLegend, UK) on ice in the dark for 30min.
Samples were washed and analysed by flow cytometry.
Immunofluorescence was analysed for 10,000 singlet events
per sample using a FACSCanto II flow cytometer (BD Biosci-
ences, UK); data were analysed using FlowJo 8.8.1 software
(TreeStar Inc., FL, USA).
2.10. Western Blot Analysis. Samples boiled in 6x Laemmli
buffer were subjected to standard SDS-PAGE (10%) and elec-
trophoretically blotted onto Immobilon-P polyvinylidene
difluoride membranes (Merck Millipore, Ltd., UK). Total
protein was quantified using Ponceau S staining (Merck
Millipore, Ltd., UK) and membranes were blotted using anti-
bodies raised against murine haem oxygenase-1 (HO-1; rab-
bit polyclonal, 1 : 1000, Cell Signaling Technology, Leiden,
The Netherlands) or superoxide dismutase 2 (SOD2; rabbit
monoclonal, 1 : 1000, Cell Signaling Technology, Leiden,
The Netherlands) in Tris-buffer saline solution containing
0.1% Tween-20 and 5% (w/v) nonfat dry milk overnight at
4°C. Membranes were washed with Tris-buffer saline
solution containing 0.1% Tween-20 and incubated with sec-
ondary antibody (horseradish peroxidase–conjugated goat
anti-rabbit 1 : 5000; Thermo Fisher Scientific, UK) for
90min at room temperature. Proteins were then detected
using enhanced chemiluminescence detection (2.5mM lumi-
nol, 0.4mM p-coumaric acid, 7.56mM H2O2 in 1M Tris,
pH8.5) and visualised on X-ray film (Scientific Laboratory
Supplies Limited, Nottingham, UK). Films were digitized
and analysed using ImageJ 1.51w software (National Insti-
tutes of Health).
2.11. Immunofluorescence and Confocal Microscopy. Follow-
ing experimental treatment, BV2 cells cultured in chambered
microslides were fixed by incubation in 2% formaldehyde in
PBS for 10min at 4°C, washed, and nonspecific antibody
binding was minimised by incubation for 30min at room
temperature in PBS containing 10% FCS and 0.05% Triton
X-100 (all Thermo Fisher Scientific, UK). Cells were then
incubated with rabbit anti-mouse p67phox monoclonal anti-
body (1 : 500, clone EPR5064, Abcam Ltd., Cambridge, UK)
and mouse anti-mouse gp91phox monoclonal antibody
(1 : 50, clone 53, BD Biosciences, UK) overnight at 4°C in
PBS with 1% FCS and 0.05% Triton X-100. Cells were washed
and incubated with AF488-conjugated goat anti-mouse and
AF647-conjugated goat anti-rabbit secondary antibodies
(both 1 : 500, Thermo Fisher Scientific, UK) in PBS with 1%
FCS and 0.05% Triton X-100 at room temperature for 1 hr.
Cells were washed with PBS, nuclei were defined by incuba-
tion with 180nM DAPI in ddH2O for 5min, and cells were
mounted under Mowiol mounting solution. Cells were
imaged using an LSM 710 Confocal Microscope (Zeiss, UK)
fitted with 405 nm, 488 nm, and 647nm lasers and a 63x oil
immersion objective lens (NA 1.4mm, working distance
0.17mm). Images were captured with ZEN Black software
(Zeiss, Cambridge, UK) and analysed with ImageJ 1.51w
(National Institutes of Health, USA).
2.12. Glucose 6-Phosphate Dehydrogenase Activity Assay.
Glucose 6-phosphate dehydrogenase (G6PD) activity was
assessed using a commercial assay (Cell Signaling Technol-
ogy, UK) according to the manufacturer’s instructions. Fol-
lowing treatment according to experimental design, cells
were lysed by ultrasonication (2 × 20 s at 20 kHz) in assay
lysis buffer (22mM Tris-HCl, 150mM NaCl, 1mM
Na2EDTA, 1mM EGTA, 1% Triton X-100, 20mM sodium
pyrophosphate, 25mM sodium fluoride, 1mM β-glycero-
phosphate, 1mM sodium orthovanadate, 1μg/ml leupeptin,
and 1mM phenylmethylsulfonyl fluoride; pH7.5, 4°C)
using a Soniprep 150 (BMG Labtech, UK) and centrifuged
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at 14,000 g and 4°C for 10min, and lysates were collected.
Samples were diluted to 0.2mg/ml in assay buffer, incubated
at 37°C for 15min with assay substrate, and fluorescence was
analysed using a CLARIOstar spectrophotometer (BMG Lab-
tech, Germany) with excitation and emission filters set at
540nm and 590 nm, respectively.
2.13. Mitochondrial Function Assay. Mitochondrial function
was assessed using a Seahorse XF24 Cell Mito Stress Test
(Agilent Technologies Inc., California, USA) according to
the manufacturer’s instructions. BV2 cells plated at 2× 106
cells/cm2 were serum starved overnight and treated accord-
ing to experimental design. Medium was replaced with Sea-
horse XF DMEM supplemented with 1 g/l glucose and
1mM sodium pyruvate, pH7.4 (Sigma-Aldrich, UK), and
cells were incubated at 37°C without CO2 for 45min prior
to analysis of oxygen consumption rate (OCR) and extracel-
lular acidification rate (ECAR). Basal respiration was initially
determined prior to subsequent serial cellular treatments
with 4μMoligomycin, 0.6μMFCCP, and 1μM rotenone/an-
timycin A to measure ATP production, maximal respiratory
capacity, and nonmitochondrial respiration, respectively. For
each treatment, readings were taken in triplicate every 5min.
Cells were lysed in RIPA buffer and protein content was
assessed by Bradford’s method for sample normalisation.
Rates of glycolytic and oxidative ATP production were then
calculated as described in [28].
2.14. Statistical Analysis. Sample sizes were calculated to
detect differences of 15% or more with a power of 0.85, and
α was set at 5%, calculations being informed by previously
published data [27, 29]. All experimental data are presented
as mean ± SEM, repeated using a minimum of n = 3 inde-
pendent culture flasks; assays were performed in triplicate.
In all cases, normality of distribution was established using
the Shapiro-Wilk test, followed by analysis with two-tailed
Student’s t tests to compare two groups or, for multiple
comparison analysis, one- or two-way ANOVA followed
by Tukey’s HSD post hoc test; a p < 0:05 was considered sta-
tistically significant. All statistical analysis was performed
using GraphPad Prism 8 software (GraphPad Software,
CA, USA).
3. Results
3.1. AD-Relevant Concentrations of Aβ Do Not Induce an
Inflammatory Response in BV2 Microglia.Whilst many stud-
ies have investigated the toxic properties of Aβ, these have in
general used micromolar concentrations of the peptide, levels
which are unlikely to be achieved until the end stages of AD
[30]. We sought to determine the potential of Fpr2/3 as a tar-
get to control Aβ-driven inflammation earlier in the disease
process when oligomeric Aβ is found in the nanomolar range
[30], hence we characterised the inflammatory response of
BV2 cells to AD-relevant concentrations of Aβ. Initial studies
identified a clear dose-dependent increase in BV2 cell reac-
tive oxygen species (ROS) production upon Aβ stimulation
(Figure 1(a)), with 100nM Aβ stimulating an approximately
2.5-fold increase; this concentration of Aβ was thus used for
further investigation.
In contrast to ROS production, however, 100 nM Aβ did
not elicit other inflammatory changes in BV2 cells, whether
assessed through production of the major inflammatory
cytokine TNFα (Figure 1(b)), induction of the inflammatory
surface phenotypic marker CD40 (Figure 1(c)), or phagocy-
tosis of labelled E. coli bioparticles (Figure 1(d)). This was
in marked contrast to the effects of bacterial lipopolysaccha-
ride (LPS) which was able to evoke a clear inflammatory
response from BV2 cells.
3.2. oAβ Induces ROS Production through NADPH Oxidase
Activation, a Response Reversed by Fpr2/3 Agonist Treatment.
Microglial ROS production via the enzyme NADPH oxidase,
also termed NOX2, is a key response to inflammatory stim-
uli, primarily serving as an antimicrobial defence mechanism
[31]. There is evidence for the activation of this enzyme in
AD [32], hence we investigated whether this was also the cel-
lular source of ROS in our model. ROS production induced
by stimulation with 100nM oAβ was sensitive to inclusion
of two different NADPH oxidase inhibitors, 1μM dipheny-
lene iodonium and 1μg/ml apocynin (Figures 2(a) and
2(b)), strongly suggesting the involvement of this enzyme.
NADPH oxidase is not the only potential cellular source of
ROS, however, with mitochondrial superoxide production
playing a significant part in many physiological and patho-
logical processes [33]. However, examination of BV2 cells
stimulated with 100 nM oAβ found no change in mitochon-
drial superoxide production over 1 hr (Supplementary
Figure 2A), whereas exposure to the mitochondrial complex
I inhibitor rotenone (1μM) resulted in a clear increase in
mitochondrial superoxide production compared to untreated
BV2 cells (Supplementary Figures 2A and 2B).
As we have previously shown that BV2 cells express
murine Fpr2/3 [29], we investigated whether activation of
this receptor could reverse oAβ-induced ROS production.
Treatment of cells with the Fpr2/3-specific agonist QC1
(100 nM), delivered 10min after oAβ-stimulation, restored
ROS production to baseline levels (Figures 2(c) and 2(d)).
Similarly, ROS production was detectable in primary murine
microglia exposed to oAβ (100 nM; Figure 2(e)). Moreover,
oAβ-induced ROS production from BV2 cells was sensitive
to pretreatment with the Fpr2/3-specific antagonist WRW4
at 10μM (Figure 2(f)). Notably, production of ROS in
response to oAβ itself was not affected by WRW4 inclusion,
indicating that oAβ is not in this case signaling through
Fpr2/3 (Figure 2(f)). Confirming these data, measurement
of total cellular H2O2 revealed that whilst this species was
undetectable in unstimulated cells, oAβ treatment caused
significant production, an effect reversed by treatment with
QC1 (Figure 2(g)).
NADPH oxidase is a multisubunit enzyme, with its acti-
vation requiring the translocation of a p67 subunit from the
cytosol to associate with the plasma membrane-bound gp91
subunit [32]. Confocal microscopic analysis of BV2 cells
stimulated with 100 nM oAβ indicated a clear appearance
of colocalised p67phox and gp91phox signal at the plasma
membrane of the cells, an effect that was again prevented
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by subsequent treatment (10min post-oAβ) with 100nM
QC1 (Figure 2(h)).
3.3. Fpr2/3 Stimulation Does Not Modify Major Cellular
Antioxidant Systems. Whilst we have shown the Fpr2/3 ago-
nist QC1 to reverse oAβ-induced NADPH oxidase activation
and ROS production, it is plausible that this could also be
achieved through activation of intracellular antioxidant sys-
tems. However, neither the ratio of reduced to oxidised gluta-
thione (Figure 3(a)) nor expressionof theantioxidant enzymes
haem oxygenase-1 (Figure 3(b)) or superoxide dismutase-2
(Figure 3(c)) was affected by treatment with either 100nM
oAβ, 100 nM QC1, or a combination of the two. These data
suggest that the ROS production-suppressing actions of
Fpr2/3 activation occur through modulation at the source
rather than stimulation of defensive systems.
3.4. Promotion of the Pentose Phosphate Pathway by oAβ Is
Reversed by Fpr2/3 Stimulation. An important aspect of
immune cell activation is a change in their preferred source
of metabolic energy, with inflammatory cells tending to
favour glycolysis over mitochondrial oxidative phosphoryla-
tion as their primary energy source [34]. We therefore inves-
tigated how oAβ treatment of BV2 cells would affect their
metabolism through the use of the Agilent Seahorse XF Ana-
lyser. Stimulation of BV2 cells with 100nM oAβ significantly
suppressed basal respiration without affecting either maxi-
mal respiration or spare respiratory capacity, an effect
reversed by treatment with 100nM QC1 1hr post-oAβ chal-
lenge (Figures 4(a)–4(e)). This change in respiration resulted
in a decrease in ATP production from both oxidative phos-
phorylation (Figure 4(f)) and glycolysis (Figure 4(g)) upon
oAβ stimulation, an action again reversed by Fpr2/3 activa-
tion with QC1 (Figures 4(f) and 4(g)).
Production of ROS from NADPH oxidase is ultimately
dependent, as its name suggests, upon a constant source of
intracellular NADPH [32]. The major source of NADPH
production in the cell is the pentose phosphate pathway,
which siphons glucose-6-phosphate from glycolysis into
the production of 6-phosphogluconate and then ribose-5-
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Figure 1: oAβ stimulates microglial ROS production without inducing an inflammatory response. (a) Treatment with oAβ dose-dependently
induces the microglial ROS production rate over a 2 hr period. (b) Treatment of BV2 cells with 50 ng/ml LPS but not 100 nM oAβ increased
microglial TNFα production after 24 and 48 hr exposure. (c) Treatment for 24 hrs with 50 ng/ml LPS but not 100 nM oAβ increased BV2 cell
surface CD40 expression. (d) Neither treatment for 24 nor 48 hrs with 100 nM oAβ affected phagocytosis by BV2 cells of heat-killed E. coli
bacterial particles. 50 ng/ml LPS increased phagocytosis at 48 hrs only. In all cases, data aremean ± SEM of 3-6 independent cultures, assayed
in triplicate. ∗p < 0:05 versus untreated cells.
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Figure 2: Continued.
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phosphate, generating NADPH in both steps [35]. As both
glycolytic and mitochondrial respiratory rates were sup-
pressed by oAβ, we investigated whether pentose phosphate
pathway activity had concomitantly risen through the mea-
surement of the activity of the rate limiting enzyme for this
pathway, glucose-6-phosphate dehydrogenase (G6PD).
Treatment of BV2 cells with 100nM oAβ for 24hrs caused
a significant increase in G6PD activity, an effect that was
reversed to baseline upon subsequent treatment with
100nM QC1 (Figure 4(h)), confirming the importance
of this pentose phosphate pathway shunt in the response
to oAβ.
3.5. oAβ Stimulated ROS Production Is Responsible for
Microglial-Mediated Neuronal Toxicity and Can Be Reversed
by Fpr2/3 Activation. Production of ROS by immune cells
is primarily for the purpose of killing invading pathogens.
In the context of AD, however, where no infectious agent
has been discovered, production of ROS may well damage
bystander neurons, contributing to neurodegeneration. To
investigate the relationship between oAβ-triggered micro-
glial ROS production and neuronal health, we employed
an in vitro coculture model using BV2 cells and trans-reti-
noic acid-differentiated SH-SY5Y cells. Initial experiments
revealed that 100nM oAβ showed no direct toxicity to
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Figure 2: oAβ-induced ROS production follows activation of NADPH oxidase and is reversed by subsequent Fpr2/3 stimulation. (a, b) oAβ-
induced ROS production was prevented by 10min pretreatment with the NADPH oxidase inhibitors DPI (1 μM, a) and apocynin (1 μg/ml,
b). (c) Representative time course of ROS production in untreated BV2 cells and cells exposed to 100 nM oAβ with or without subsequent
stimulation with 100 nM QC1 (10min post-oAβ). (d) Average ROS production rates for BV2 cells treated with oAβ (100 nM, 1 hr) with
or without subsequent stimulation with 100 nM QC1 (10min post-oAβ). (e) Treatment for 1 h of primary murine microglia from wild-
type mice with 100 nM oAβ induced significant ROS production. (f) Inclusion of the selective Fpr2/3 antagonist WRW4 (10 μM, 10min
prior to oAβ treatment) did not affect 100 nM oAβ-induced ROS production but prevented the effects of subsequent treatment with QC1
(100 nM, 10min post-oAβ). (g) Treatment of BV2 cells for 1 h with oAβ (100 nM) induced significant production of the ROS hydrogen
peroxide, an effect blocked by subsequent treatment with QC1 (100 nM, 10min post-oAβ). (h) Treatment of BV2 cells for 30min with
100 nM oAβ stimulated colocalisation of the NADPH oxidase subunits p67phox (green) and gp91phox (red), an effect prevented by
treatment with 100 nM QC1 administered 10min post-oAβ. Nuclei are counterstained with DAPI (blue); p67phox and gp91phox
colocalisation intensity is represented by the false-colour plots. Graphical data are mean ± SEM of 3-6 independent cultures, assayed in
triplicate ∗p < 0:05. Images represent cells from 3 independent cultures; scale bar = 10μm.
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differentiated SH-SY5Y cells even after exposure for 24hrs
(Figure 5(a)). However, administration of oAβ to cocultures
significantly and selectively enhanced apoptosis of SH-SY5Y
cells (Figures 5(b) and 5(c)) without affecting BV2 cell sur-
vival (Figure 5(c)), an effect that was notably prevented by
treatment with 100nM QC1 1hr after oAβ exposure. Nota-
bly, differentiated SH-SY5Y cells did not express Fpr2/3
(Supplementary Figure 3). Confirming that either direct
contact or short-lived secretory factors were responsible for
BV2 cell-mediated toxicity, apoptosis of SH-SY5Y cells was
not induced following treatment with conditioned medium
from oAβ-stimulated BV2 cultures (Figure 5(d)). Finally, to
test whether BV2 cell ROS production was the mediating
agent for SH-SY5Y cytotoxicity, the experiment was repeated
in the presence of the antioxidant molecule α-tocopherol
(10μM). Inclusion of this antioxidant prevented SH-SY5Y
apoptosis in cocultures treated with oAβ, indicating a direct
mediatory role of microglial ROS production.
4. Discussion
Despite over 300 clinical trials having been performed tar-
geting either of the proposed toxic mediators in AD, Aβ
and hyperphosphorylated tau, we do not as yet have any
successful therapeutic approaches for the disease. This sug-
gests that, at the least, these two proteins cannot be the sole
factors driving the disease [36]. Increasingly, the role of neu-
roinflammation and the behaviour of microglia in AD has
come under investigation [3, 37], an approach given further
impetus by reports that ablation of microglia can halt brain
atrophy in murine models of Aβ-driven disease [38] and
tauopathy [39]. Microglial activation can be both beneficial
and damaging, hence strategies that can control excessive
inflammatory activity and promote a proresolving pheno-
type may be of great potential for therapeutic use. In this
study, we have used an in vitro cellular model to provide
proof-of-principle evidence for the targeting of the proresol-
ving receptor Fpr2/3 as a mechanism to restrain microglial
behaviour and limit the ability of these cells to damage
bystander neurons.
Here, we report that alongside its well-characterised
function in resolving inflammation and efferocytosis [40],
Fpr2/3 activation can reverse oAβ-induced ROS production
through deactivation of NADPH oxidase activity. Activation
of microglial NADPH oxidase by oAβ is well supported [41,
42] and may be critical in triggering neuroinflammation,
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Figure 3: Neither treatment with oAβ nor QC1 affected major cellular antioxidant systems. (a) The ratio of reduced (GSH) to oxidised
(GSSG) glutathione within BV2 cell cytoplasm was not affected by either oAβ (100 nM, 2 hrs) or QC1 (100 nM, 10min post-oAβ)
administration. (b) Expression of the antioxidant enzyme haem oxygenase-1 (HO-1) was not affected by treatment with oAβ (100 nM,
6 hrs) or QC1 (100 nM, 10min post-oAβ). Sample loading was normalised to Ponceau S-defined total protein content; densitometric
analysis data are mean ± SEM of 3 independent cultures. (c) Expression of the antioxidant enzyme superoxide dismutase 2 (SOD2) was
not affected by treatment with oAβ (100 nM, 24 hrs) or QC1 (100 nM, 10min post-oAβ) or the alternative Fpr2/3 agonist Cpd43 (100 nM,
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Figure 4: Treatment with oAβ suppresses mitochondrial respiration and promotes activity of the pentose phosphate pathway, effects
reversed by subsequent activation of Fpr2/3. (a) Typical oxygen consumption rates of untreated BV2 cells and cells treated for 24 hrs with
100 nM oAβ with or without subsequent stimulation with QC1 (100 nM, 1 hr post-oAβ) and administration times for oligomycin (4 μM),
FCCP (0.6 μM), and rotenone with antimycin A (both 1μM) are indicated. (b) Typical extracellular acidification rates for untreated BV2
cells and cells treated for 24 hrs with 100 nM oAβ with or without subsequent stimulation with QC1 (100 nM, 1 hr post-oAβ) and
administration times for oligomycin (4 μM), FCCP (0.6 μM), and rotenone with antimycin A (both 1μM) are indicated. (c–e) Treatment
with 100 nM oAβ for 24 hrs significantly suppressed basal metabolic rate (c), an effect that no longer reached statistical significance after
QC1 treatment (100 nM, 1 hr post-oAβ). In contrast, neither oAβ nor QC1 treatment affected maximal respiration (d) or spare
respiratory capacity (e). (f) Treatment with oAβ (100 nM, 24 hrs) significantly suppressed basal, but not maximal, ATP production due to
mitochondrial oxidative phosphorylation, an effect reversed by subsequent treatment with QC1 (100 nM, 1 hr post-oAβ). (g) ATP
generation from glycolysis was unaffected by either oAβ or QC1 treatment. (h) Activity of the rate-determining enzyme of the pentose
phosphate pathway, glucose-6-phosphate dehydrogenase (G6PD), was significantly increased by treatment with 100 nM oAβ (24 hrs), an
effect reversed by subsequent stimulation with 100 nM QC1 (1 hr post-oAβ). All data are mean ± SEM for 3-5 independent cultures,
assayed in triplicate, ∗p < 0:05.
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given the damaging effects of oxidative stress for neurons,
as has been reported in traumatic brain injury [43]. Future
work will determine whether the in vitro findings we
report here can be extended to the in vivo situation, but
if so, they suggest that the use of Fpr2/3 agonists capable
of reversing NADPH oxidase activation may be of thera-
peutic potential for AD.
The effects of Fpr2/3 activation upon oAβ-induced ROS
production are mirrored by changes in microglial metabolic
phenotype. The importance of cellular metabolism in regulat-
ing immune cell phenotype has become increasingly evident
over the past few years, with a shift frommitochondrial respi-
ration to a glycolysis-dominant metabolism being closely
associated with a proinflammatory phenotype [34]. Meta-
bolic changes in AD are well supported [44], but the relation-
ship between these changes and disease pathology is unclear.
In the current study, exposure ofmicroglia to oAβ suppressed
mitochondrial respiration, but rather than being accompa-
nied by changes to glycolysis, it was associated with a signifi-
cant diversion of glucose to the pentose phosphate pathway.
Presumably, this was due to increased NADPH demand asso-
ciated with NADPH oxidase-driven ROS production, as seen
in peripheral macrophages [45]. Notably, Fpr2/3 agonist
treatment was able to reverse the effects of oAβ on microglial
metabolism, targeting both the pentose phosphate pathway
and the mitochondria. This data adds to the increasing evi-
dence suggesting that Fpr2/3 not only suppresses proinflam-
matory mediator production [16, 46] but also aids in the
regulation of the underlying metabolic changes that occur
in activated immune cells, as we have recently shown in
peripheral macrophages [14]. Importantly, microglia rapidly
upregulate Fpr2/3 expression following inflammatory insult
[47], and whilst the effects of its stimulation on neuroinflam-
mation can be agonist dependent [48], selective Fpr2/3 acti-
vation contributes to neuroinflammatory resolution in a
murine model of AD [46].
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Figure 5: Treatment with oAβ induces differentiated SH-SY5Y neuronal apoptosis only in the presence of microglia, acting through Fpr2/3-
sensitive ROS release. (a) Treatment with oAβ (100 nM, 48 hrs) had no effect on trans-retinoic acid- (tRA-) differentiated SH-SY5Y cell
viability; data are mean ± SEM of 5 independent cultures, assayed in triplicate. (b) Separation of tRA-differentiated SH-SY5Y neurons
from BV2 cells grown in coculture on the basis of differential CD200 and CD11b expression; plot is representative of 3 independent
cultures. (c) Treatment of cocultures of BV2 and tRA-differentiated SH-SY5Y neurons with oAβ (100 nM, 48 hrs) induces significant
SH-SY5Y apoptosis, an effect prevented by subsequent treatment with QC1 (100 nM, 10min post-oAβ). (d) Conditioned medium from
BV2 cells treated or not with 100 nM oAβ (24 hrs) had no effect on tRA-differentiated SH-SY5Y neuronal apoptosis following exposure
for 48 hrs. (e) Inclusion of the antioxidant α-tocopherol (10 μM) in cocultures of BV2 cells and tRA-differentiated SH-SY5Y neurons
prevented oAβ-induced (100 nM, 48 hrs) neuronal apoptosis; data are mean ± SEM for 3-6 independent cultures, assayed in triplicate,
∗p < 0:05.
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However, a notable finding of the current work is that we
were unable to detect evidence for an oAβ-induced micro-
glial inflammatory response, in contrast to previous in vitro
studies [24, 47, 49]. This does not appear to be due to a defi-
ciency in the BV2 cells themselves, as stimulation with bacte-
rial lipopolysaccharide was still able to trigger a potent
inflammatory response. Notably, studies that report proin-
flammatory effects of oAβ have commonly used micromolar
concentrations of the peptide, several orders of magnitude
greater than levels reported to occur in the human brain in
AD [30], at least in early stages of the disease. Local accumu-
lations of a variety of Aβ forms, including oligomeric and
fibrillar, may exert further toxic effects, but given the tempo-
ral discrepancy between Aβ plaque and symptom appearance
in humans [50], this may not be as relevant to the initiation
stages of the disease. Moreover, this mismatch suggests that
the direct proinflammatory effects of oAβ seen in vitro may
not be fully recapitulated in vivo, although this requires fur-
ther validation. Nevertheless, oAβ was clearly able to induce
ROS production at levels capable of damaging bystander
cells, which if replicated in vivo may be a driving factor in
the ongoing neuronal damage and secondary neuroinflam-
mation seen in AD. Production of ROS is far from the
sole damaging effect of oAβ in the brain, as is borne out
by the, at best, equivocal results from clinical trials of anti-
oxidants in AD [49, 51]. Nevertheless, targeting a receptor
with the potential to suppress ROS production, restore
microglial metabolic homeostasis, and promote resolution,
as is the case for Fpr2/3, has significant potential for ther-
apeutic development.
The goal of this study was to provide proof-of-principle
evidence that exploitation of human FPR2 may hold promise
as a therapeutic target for AD research. Evidently, there are
limitations in how far the current study should be inter-
preted, with a particular need for further in vivo validation
of our findings. Nonetheless, the data presented do suggest
that this receptor would be a suitable target for antioxidative
and metabolic therapeutic development for further AD
research, particularly as the effects of Fpr2/3 stimulation were
apparent when stimulation occurred after oAβ treatment.
This study therefore adds novel insights into the role of
Fpr2/3 in modulating microglial oxidative stress and metab-
olism, holding promise for select Fpr2/3 agonists as potent
and effective treatment options for inflammatory disease [9].
5. Conclusions
This study has identified that although pathologically rele-
vant concentrations of oAβ do not appear to directly stimu-
late an inflammatory microglial phenotype, oAβ at these
levels is a potent activator of microglial ROS production via
NADPH oxidase, consequently altering metabolic pheno-
type. Moreover, activation of the proresolving receptor
Fpr2/3 was able to reverse these oAβ-induced changes and
protect bystander neurons from damage. These data suggest
that manipulation of Fpr2/3 may be an important target for
future therapeutic development in neuroinflammatory con-
ditions such as Alzheimer’s disease.
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Supplementary Materials
Supplementary Figure 1: approximate molecular weight of
Aβ1-42 oligomers following polyacrylamide gel electrophore-
sis under nondenaturing conditions. As monomeric Aβ1-42
has a molecular weight of 4.51 kDa, the apparent molecular
weight of approximately 35 kDa suggests that oAβ species
were hexamers/heptamers. Supplementary Figure 2: mito-
chondrial ROS production is not stimulated in microglia by
oAβ treatment. (A) Representative time course of mitochon-
drial superoxide production in untreated BV2 cells and cells
exposed to 100nM oAβ, 100 nM QC1, or 1μM rotenone
for 1 hr. (B) Average mitochondrial superoxide production
rates for untreated BV2 cells and cells treated with oAβ
(100 nM, 1 hr), QC1 (100 nM, 1 hr), or rotenone (ROT;
1μM, 1hr); data are mean ± SEM of 4 independent cultures,
assayed in triplicate, ∗p < 0:05. Supplementary Figure 3:
FPR2 is not expressed by SH-SY5Y cells. (A) Representative
forward scatter-side scatter histogram plot and gating
strategy. (B) Representative histogram plot to exclude cell
doublets. (C) Histogram of relative FPR2 staining. Neither
naïve or trans-retinoic acid induced differentiated SH-SY5Y
cells expressed FPR2. (Supplementary Materials)
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